ArticleAmerican journal of neurodegenerative disease2012
Microglial chemotactic signaling factors in Alzheimer's disease.
Article in American journal of neurodegenerative disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Amyotrophic lateral sclerosis stratification: unveiling patterns with virome, inflammation, and metabolism molecules.Journal of neurology · 2024Article
- Neuron-Microglia Crosstalk in Neuropsychiatric Disorders.Advances in experimental medicine and biology · 2023Review
- MicroRNA: A Linking between Astrocyte Dysfunction, Mild Cognitive Impairment, and Neurodegenerative Diseases.Life (Basel, Switzerland) · 2022Review
- Integrative analysis of DNA methylation and gene expression identifies genes associated with biological aging in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases.CNS drugs · 2021Review
- Cytokine-, Neurotrophin-, and Motor Rehabilitation-Induced Plasticity in Parkinson's Disease.Neural plasticity · 2020Review
- Pulmonary hypertension: Pathophysiology beyond the lung.Pharmacological research · 2020Review
- The Interplay Between Beta-Amyloid 1-42 (AβFrontiers in molecular neuroscience · 2020Article
- Long noncoding RNA MALAT1 acts as a competing endogenous RNA to regulate Amadori-glycated albumin-induced MCP-1 expression in retinal microglia by a microRNA-124-dependent mechanism.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Article
- Migration-based selections of antibodies that convert bone marrow into trafficking microglia-like cells that reduce brain amyloid β.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Characterizing microglia activation: a spatial statistics approach to maximize information extraction.Scientific reports · 2017Article
- Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health.Stem cell research & therapy · 2017Article
- Rhinacanthin C Alleviates Amyloid-Oxidative medicine and cellular longevity · 2017Article
- The effect of abscisic acid chronic treatment on neuroinflammatory markers and memory in a rat model of high-fat diet induced neuroinflammation.Nutrition & metabolism · 2016Article
- Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease.Journal of neuroinflammation · 2015Article
- Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.Translational psychiatry · 2014Article
- Microglial dysfunction in brain aging and Alzheimer's disease.Biochemical pharmacology · 2014Review
- Advances in blood-based protein biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2013Review
- Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The net migration of microglia induced by deposits of amyloid beta (Aβ) constitutes a chemotactic response of resident neuroimmune brain cells. This process serves to localize clusters of microglia nearby Aβ deposits preparatory to cellular activation and functional responses. Microglial responses to Aβ deposits localized in brain parenchyma and in blood vessels lead to acute and chronic neuroinflammation in Alzheimer's disease (AD) brain. This review summarizes studies on the prominent chemotactic factors MCP-1, MIP-1α and IL-8 and also includes recent work indicating VEGF and fractalkine as chemotactic agents. The possibility that microglial release of MCP-1 may play a role in mediating chemotactic responses of neural progenitor cells is also considered. The plethora of chemotactic factors and their cognate receptors suggests the utility in testing pharmacological modulation of chemotaxis for effects to inhibit chronic neuroinflammation and confer neuroprotection in AD animal models.
Indexed as
Identifiers
23383392PMC3560464W63680513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.